Fluorescent aptasensor based on magnetic bead-assisted displacement reaction for monitoring vancomycin in plasma.
Summary
A magnetic bead-assisted fluorescent aptasensor quantifies plasma vancomycin via displacement of cDNA from an aptamer, enabling rapid fluorescence readout. Optimized with a 16-mer cDNA and magnesium-containing PBS, the assay agreed well with ELISA in clinical samples, supporting its accuracy and clinical utility.
Key Findings
- Aptasensor uses magnetic bead-assisted displacement of cDNA from a fluorescent aptamer upon vancomycin binding.
- Optimized conditions included a 16-mer cDNA and PBS containing 10 mM MgCl.
- Clinical plasma testing showed good agreement with ELISA, supporting accuracy and applicability.
Clinical Implications
Could enable faster vancomycin dose optimization at the point of care, decreasing turnaround time and potentially improving safety by minimizing nephrotoxicity through better TDM.
Why It Matters
Introduces a simple, rapid, and cost-effective TDM tool that can reduce assay time and matrix interference versus conventional immunoassays, with clinical-sample validation.
Limitations
- Clinical outcome impact of faster TDM was not assessed.
- Analytical robustness across broader patient matrices and potential interferents requires further evaluation.
Future Directions
Integrate into portable point-of-care devices, benchmark against LC-MS/MS, and expand to multiplex TDM panels.
Study Information
- Study Type
- Analytical validation study
- Research Domain
- Diagnosis
- Evidence Level
- V - Preclinical/analytical validation without patient outcome data
- Study Design
- OTHER